Deliver Your News to the World

Nanobac Life Sciences Announces Potential Link Between Nanobacteria and Astronaut’s Kidney Stones


WEBWIRE

TAMPA, FL -- Jan. 18, 2005 -- Nanobac Life Sciences, Inc. (OTCBB:NNBP) announces the publication of “A potential cause for kidney stone formation during space flights: Enhanced growth of Nanobacteria in microgravity” in Kidney International, (2005) 67, 483-491. Neva Ciftcioglu, Director of Science at Nanobac Life Sciences, Inc., and a team of NASA scientists used multiple techniques to determine that Nanobacteria infection multiplies faster in space flight simulated conditions than on Earth.

This discovery may prove to be critical for future exploratory missions to the moon and Mars. Astronauts are at an increased risk for kidney stones on long duration missions. Nanobacteria appear to be a stressor that may be a limiting factor for these missions. Nanobacteria are a unique organism that is thought to be the initiator of kidney stone formation. Since they grow faster in a microgravity environment this may explain why astronauts get kidney stones on space missions.

This novel concept opens the door for new diagnostic and therapeutic techniques addressing nanobacterial infection in kidney stones. Kidney stones can be debilitating and affect 20 million Americans and recur in 50% of patients within 5 years. Nanobac will continue to collaborate with NASA to investigate the link between nanobacterial infection and astronaut health which may lead to new diagnostics and therapies.

About Nanobac Life Sciences

Nanobac Life Sciences, Inc. is dedicated to improving people’s health through the detection and eradication of Nanobacterium sanguineum (Nanobacteria). The Company’s pioneering research is establishing the pathogenic role of Nanobacteria in calcification, particularly in coronary artery heart disease and vascular disease. Nanobac has identified two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacterial antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop the first FDA approved therapeutic to treat nanobacterial infection. The Company currently markets a patented nanobiotic regimen. For further information concerning our nanobiotic, please visit http://www.nanobacsciences.com.

Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our website at: http://www.nanobaclifesciences.com.

Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as ”believes,“ ”anticipates,“ ”intends,“ ”plans,“ ”expects" and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.



WebWireID1070





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.